[The Possibilities of Pharmacological Correction of Endothelial Dysfunction in Patients With Arterial Hypertension]

Kardiologiia
|April 30, 2016
PubMed

Insights

Fixed-dose perindopril arginine and amlodipine combination therapy effectively reduced endothelial dysfunction and lowered blood pressure in patients with arterial hypertension. This treatment achieved target blood pressure in 71.4% of patients within 12 weeks.

Area of Science:

  • Cardiology
  • Pharmacology
  • Vascular Medicine

Background:

  • Endothelial dysfunction (ED) is a key factor in arterial hypertension (AH).
  • Managing AH often requires addressing underlying vascular issues like ED.
  • Fixed-dose combinations offer a simplified therapeutic approach.

Purpose of the Study:

  • To evaluate the efficacy of a fixed-dose combination of perindopril arginine and amlodipine.
  • To assess the impact of this combination on endothelial dysfunction in hypertensive patients.
  • To determine if this therapy helps achieve target blood pressure levels.

Main Methods:

  • A 12-week study involving 49 patients with hypertension and ED.
  • Patients received a combination of perindopril arginine and amlodipine tailored to their blood pressure.
  • Endothelial function and blood pressure were assessed at baseline and after 12 weeks.

Main Results:

  • Mean systolic blood pressure decreased from 162.6 to 131.1 mmHg; diastolic decreased from 95.4 to 78.7 mmHg (p < 0.05).
  • Endothelial dysfunction improved, with the proportion of patients with both types of ED decreasing from 71.4% to 57.1% (p < 0.05).
  • Target blood pressure was achieved in 71.4% of patients by the study's end, with a low incidence of adverse events (2.1-4.2%).

Conclusions:

  • Combination therapy with perindopril arginine and amlodipine is effective in managing hypertension and endothelial dysfunction.
  • This fixed-dose combination significantly reduces blood pressure and improves vascular function in working-age adults.
  • The treatment regimen achieved target blood pressure in a majority of patients with a favorable safety profile.
Abstract

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
537
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.4K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
697
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
506
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
571